Clinical and prognostic usefulness of serum proteomic profile in hepatic colorectal metastases: a pilot prospective study.
OBJECTIVE
To analyze the use of proteomic profiles to discriminate healthy from patients with colorectal liver metastases (CLM) and to predict neoplastic recurrence after CLM resection.


METHODS
From April 2005 to October 2008, 70 patients operated for first curative resection of CLM and 60 healthy controls underwent determination of preoperative serum proteomic profile. We performed a preliminary training with patients and controls and obtained a classification system based on these patients' proteomic profiles training. The system was then tested about the ability to predict the colon versus rectum origin, metachronous or synchronous appearance, risk of recurrence after CLM resection and whether a sample was from a control or a CLM patient.


RESULTS
Sensitivity, specificity, positive and negative predictive values for detecting CLM patients were 75, 100, 100 and 54.6 %, respectively. Best CLM appearance time identification was 50 % and primary tumor origin identification was 62.5 %. Best classifications of neoplastic recurrence within the first year after CLM resection and during the follow-up period were 47.5 and 45 %, respectively. Larger training sets and prevalence-based training sets led to better classification of patients and characteristics.


CONCLUSIONS
Proteomic profiles are a promising tool for discriminating CLM patients from healthy patients and for predicting neoplastic recurrence.
Liver Surgery and Transplantation Unit, Digestive and Metabolism Diseases Clinical Institute, IDIBAPS, Hospital Clinic and Provincial, CIBERehd, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
J
J
Martí
J
J
Fuster
J M
JM
Estanyol
F
F
Fernández
R
R
Deulofeu
J
J
Ferrer
A
A
Pelegrina
A
A
Reyes
C
C
Fondevila
J C
JC
García-Valdecasas
D000368:Aged; D001798:Blood Proteins / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000097:blood* / Q000473:pathology*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood* / Q000556:secondary*; D008297:Male; D013058:Mass Spectrometry; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010865:Pilot Projects; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D020543:Proteome; D040901:Proteomics / Q000379:methods*; D012008:Recurrence; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D001798:Blood Proteins; D020543:Proteome